Duncan Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.22 Cr
- Revenue Growth -1.12%
- Profit Growth 13.94%
- Ebitda 13.55%
- Net Worth -41.17%
- Total Assets -52.58%
About Duncan Pharma
Duncan Pharma Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 May 2005 and has a history of 19 years and eight months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹1.22 Cr.
Ida Ebenezar and Varadarajan Dhivyalakshmi serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231TN2005PTC056343
-
Company No.
056343
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 May 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Duncan Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ida Ebenezar
|
Director | 20-Apr-2020 | Current |
|
Varadarajan Dhivyalakshmi
|
Director | 20-Apr-2020 | Current |
Financial Performance of Duncan Pharma.
Duncan Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.12% decrease. The company also saw a substantial improvement in profitability, with a 13.94% increase in profit. The company's net worth observed a substantial decline by a decrease of 41.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Duncan Pharma?
In 2020, Duncan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kniss Laboratories Private LimitedVaradarajan Dhivyalakshmi is a mutual person
Charges (Loans)
₹12.16 M
₹0
Charges Breakdown by Lending Institutions
- Karur Vysya Bank Ltd. : 0.75 Cr
- Karur Vysya Bank Limited : 0.40 Cr
- Through Dy. Director Of Industries Single Window Clearance Agency : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Nov 2010 | Through Dy. Director Of Industries Single Window Clearance Agency | ₹0.66 M | Open |
| 23 Jun 2006 | Karur Vysya Bank Limited | ₹4.00 M | Open |
| 23 Jun 2006 | Karur Vysya Bank Ltd. | ₹7.50 M | Open |
How Many Employees Work at Duncan Pharma?
Unlock and access historical data on people associated with Duncan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duncan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duncan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
